Opioid and Cannabinoid Interactions
Purpose
This study will examine the effects of doses of marijuana/placebo and doses of opioid/placebo, alone and in combination. The primary outcomes are related to pharmacodynamic measures (subjective ratings of drug liking and other abuse-related effects; physiological outcomes) to determine the interaction effects of these compounds.
Conditions
- Marijuana Usage
- Opioid Use
Eligibility
- Eligible Ages
- Between 18 Years and 50 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Healthy adults ages 18-50 - Current non-medical use of opioids and marijuana
Exclusion Criteria
- Physical dependence on opioids, alcohol benzodiazepines/sedative/hypnotics - Seeking treatment for drug use - Significant medical problems
Study Design
- Phase
- Phase 1
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Sequential Assignment
- Primary Purpose
- Basic Science
- Masking
- Double (Participant, Investigator)
- Masking Description
- This is a randomized, double-blind, double-dummy, placebo-controlled design
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental Vaporized Marijuana |
Participants will receive non-therapeutic, experimental doses of active vaporized marijuana. Active marijuana will be administered once per session and will be administered via a vaporizer. |
|
Experimental Opioid Agonist |
Participants will receive non-therapeutic, experimental doses of an active opioid agonist. Active opioid agonist will be administered once per session and will be administered intranasally (snorting). |
|
Experimental Opioid Agonist/Marijuana Combination |
Participants will receive non-therapeutic, experimental doses of active opioid in combination with non-therapeutic, experimental doses of active vaporized marijuana. Opioid and marijuana doses will be administered once during each session. It is possible to receive both active drugs on the same day. Opioid doses will be administered intranasally; marijuana doses will be administered via vaporizer. |
|
Placebo Comparator Placebo |
Participants will receive non-therapeutic, experimental doses of placebo. Opioid doses will be administered intranasally; marijuana doses will be administered via vaporizer. |
|
Recruiting Locations
More Details
- NCT ID
- NCT03705559
- Status
- Completed
- Sponsor
- Shanna Babalonis, PhD